Wei Zhang

Dr. Wei Zhang

Wake Forest Baptist Comprehensive Cancer Center
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
Chao GaoChao Gao
Chao Gao
YWYingmei Wang
Yingmei Wang
RBRussell Broaddus
Russell Broaddus
LSLonghao Sun
Longhao Sun
FXFeng-Xia Xue
Feng-Xia Xue
WZWei Zhang
Wei Zhang
Exon 3 mutations of CTNNB1 drive tumorigenesis: A Review Exon 3 mutations of CTNNB1 drive tumorigenesis: A Review

29 April 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
QSQianqian Song
Qianqian Song
GHGregory A. Hawkins
Gregory A. Hawkins
LWLeonard Wudel
Leonard Wudel
PCPing‐Chieh Chou
Ping‐Chieh Chou
EFElizabeth Forbes
Elizabeth Forbes
WZWei Zhang
Wei Zhang
Tumor‐infiltrating myeloid cells are the most abundant leukocyte population within tumors. Molecular cues from the tumor microenvironment promote the differentiation of immature myeloid cells toward an immunosuppressive phenotype. However, the in situ dynamics of the transcriptional reprogramming underlying this process are poorly understood. Therefore, we applied single cell RNA‐seq (scRNA‐seq) to computationally investigate the cellular composition and transcriptional dynamics of tumor and adjacent normal tissues from 4 early‐stage non‐small cell lung cancer (NSCLC) patients. Our scRNA‐seq analyses identified 11 485 cells that varied in identity and gene expression traits between normal and tumor tissues. Among these, myeloid cell populations exhibited the most diverse changes between tumor and normal tissues, consistent with tumor‐mediated reprogramming. Through trajectory analysis, we identified a differentiation path from CD14+ monocytes to M2 macrophages (monocyte‐to‐M2). This differentiation path was reproducible across patients, accompanied by increased expression of genes (eg, MRC1/CD206, MSR1/CD204, PPARG, TREM2) with significantly enriched functions (Oxidative phosphorylation and P53 pathway) and decreased expression of genes (eg, CXCL2, IL1B) with significantly enriched functions (TNF‐α signaling via NF‐κB and inflammatory response). Our analysis further identified a co‐regulatory network implicating upstream transcription factors (JUN, NFKBIA) in monocyte‐to‐M2 differentiation, and activated ligand‐receptor interactions (eg, SFTPA1‐TLR2, ICAM1‐ITGAM) suggesting intratumoral mechanisms whereby epithelial cells stimulate monocyte‐to‐M2 differentiation. Overall, our study identified the prevalent monocyte‐to‐M2 differentiation in NSCLC, accompanied by an intricate transcriptional reprogramming mediated by specific transcriptional activators and intercellular crosstalk involving ligand‐receptor interactions.

10 January 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
TLTao Li
Tao Li
MFM. Elizabeth Forbes
M. Elizabeth Forbes
GFGregory N. Fuller
Gregory N. Fuller
JLJiabo Li
Jiabo Li
XYXuejun YANG
Xuejun YANG
WZWei Zhang
Wei Zhang

22 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
QSQianqian Song
Qianqian Song
JSJing Su
Jing Su
WZWei Zhang
Wei Zhang
Single-cell omics is the fastest-growing type of genomics data in the literature and public genomics repositories. Leveraging the growing repository of labeled datasets and transferring labels from existing datasets to newly generated datasets will empower the exploration of single-cell omics data. However, the current label transfer methods have limited performance, largely due to the intrinsic heterogeneity among cell populations and extrinsic differences between datasets. Here, we present a robust graph artificial intelligence model, single-cell Graph Convolutional Network (scGCN), to achieve effective knowledge transfer across disparate datasets. Through benchmarking with other label transfer methods on a total of 30 single cell omics datasets, scGCN consistently demonstrates superior accuracy on leveraging cells from different tissues, platforms, and species, as well as cells profiled at different molecular layers. scGCN is implemented as an integrated workflow as a python software, which is available at https://github.com/QSong-github/scGCN.

31 March 2018 in Cancer Communications
Verified
Journal Article
Open access
PDF file
YLYan Li
Yan Li
WZWei Zhang
Wei Zhang
Precision medicine just witnessed two breakthroughs in oncology in 2017. Pembrolizumab (Keytruda), Merck's anti‐programmed cell death‐1 (PD‐1) monoclonal antibody (mAb), received accelerated approval in May 2017 by the US Food and Drug Administration for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having microsatellite instability‐high (MSI‐H) or deficient DNA mismatch repair (dMMR). Shortly after, nivolumab (Opdivo), Bristol‐Myers Squibb's anti‐PD‐1 mAb, gained an accelerated approval in August 2017 for adult and pediatric patients with MSI‐H or dMMR metastatic colorectal cancer that has progressed after standard chemotherapy. These regulatory approvals marked an important milestone that a cancer treatment may be approved based on a common biomarker rather than the anatomic location in the body where the tumor originated, and therefore established a precedent for tumor type‐agnostic therapy. In the 2017 American Society for Clinical Oncology annual meeting, larotrectinib (LOXO‐101), Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTRK)‐fusion proteins in adult and pediatric patients. Both the anti‐PD‐1 mAbs and the TRK‐targeting therapies share some basic features: (a) biomarker‐based, well‐defined rare patient population; (b) exceptionally high clinical efficacy, e.g., near 40% overall response rate (ORR) for pembrolizumab across 15 tumor types with MSI‐H/dMMR and 75% ORR for larotrectinib across more than 12 tumor types with NTRK‐fusion proteins; (c) durable responses lasting at least 6 months with complete responses observed; and (d) parallel development in adult and pediatric populations. With increasing accessibility to genetic analysis tools such as next‐generation sequencing, tumor type‐agnostic therapy has become a reality, both during clinical development and in clinical practice. Adjustments in our approaches to developing new anti‐cancer drugs and to adopting these new cancer treatments in clinical practice need to occur in order to prepare ourselves for the new era of precision medicine.

16 January 2018 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
XLX.C. Li
X.C. Li
MWM.Y. Wang
M.Y. Wang
MYM. Yang
M. Yang
HDH.J. Dai
H.J. Dai
BZB.F. Zhang
B.F. Zhang
KCKexin Chen
Kexin Chen
Esophageal squamous cell carcinoma (ESCC) is often diagnosed at an advanced and incurable stage. Information on driver genes and prognosticators in ESCC remains incomplete. The objective was to elucidate significantly mutated genes (SMGs), mutational signatures, and prognosticators in ESCC. Three MutSig algorithms (i.e. MutSigCV, MutSigCL and MutSigFN) and ‘20/20+’ ratio-metric were employed to identify SMGs. Nonnegative matrix factorization was used to decipher mutational signatures. Kaplan–Meier survival analysis, multivariate Cox and logistic regression models were applied to analyze association between mutational features and clinical parameters. We identified 26 SMGs, including 8 novel (NAV3, TENM3, PTCH1, TGFBR2, RIPK4, PBRM1, USP8 and BAP1) and 18 that have been previously reported. Three mutational signatures were identified to be prevalent in ESCC including clocklike C>T at CpG, APOBEC overactive C>T at TpCp[A/T], and a signature featured by T>C substitution. The T>C mutational signature was significantly correlated with alcohol consumption (OR: 3.59; 95% CI: 2.30–5.67; P < 0.001). This alcohol consumption signature was also observed in liver cancer and head and neck squamous cell carcinoma, and its mutational activity was substantially higher in samples with mutations in TP53. Survival analysis revealed that TENM3 mutations (HR: 5.54; CI: 2.68–11.45; P < 0.001) and TP53 hotspot mutation p.R213* (HR: 3.37; CI: 1.73–8.06; P < 0.001) were significantly associated with shortened survival outcome. The association remained statistically significant after controlling for age, gender, TNM stage and tumor grade. We have uncovered several new SMGs in ESCC and defined an alcohol consumption related mutational signature. TENM3 mutations and the TP53 hotspot mutation p.R213* are independent prognosticators for poor survival in ESCC.